What is the preferred concentration of ethanolamine oleate for sclerotherapy of oral vascular anomalies?

Abstract

Background This study compared three different concentrations of EO (1.25%, 2.5% and 5%) for the treatment of oral vascular anomalies (OVAs). Material and Methods This was a retrospective comparative analysis of patients with OVAs treated with EO. Anomalies smaller than 20 mm were included. The patients were treated with 1.25% (G1), 2.5% (G2), and 5% (G3) and clinical data were obtained. The number of sessions, the final volume and dose of EO were statistically analyzed to verify effectiveness and safety of the treatment. The different concentrations of EO were compared considering the number of sessions, the final volume and total dose of EO. Analysis of covariance (ANCOVA) was used to evaluate the influence of covariates on the outcomes. A p -value < 0.05 was considered significant. Results Nineteen women and 11 men with a median age of 54 years were included. The OVAs were most frequent in the lip (n=14) and cheek (n=9). All lesions exhibited complete clinical healing within 28 days. Patients of G3 required fewer sessions than those of G2 ( p =0.017), a lower final volume compared to the other groups ( p <0.001), and a lower total dose than G1 ( p <0.001). Patients of G1 used a lower total dose than G2 ( p =0.003). Conclusions The concentration of 5% EO performed better than 1.25% and 2.5% for sclerotherapy of OVAs measuring up to 20 mm. This preliminary result should be the preferred concentration of EO to provide an effective and safe treatment of OVAs. Key words: Ethanolamine oleate, sclerotherapy, vascular malformations, hemangioma, oral mucosa.

Extensive vascular malformation in the face treated by sclerotherapy with 5% ethanolamine oleate foam

“…Monoethanolamine oleate produces a dose‐dependent inflammatory response, resulting in fibrosis and possible vascular occlusion 25 Kato et al 26 evaluated the treatment of oral lesions with monoethanolamine oleate at concentrations of 1.25%, 2.5% and 5%. The concentration at 5% showed better performance, requiring fewer sessions and lower final volume.…”

Evaluation of sclerotherapy with different dilutions of ethanolamine oleate in the treatment of oral varicose veins

“…Kato et al stated that a single puncture may not be enough to dissipate the agent throughout the lesion, which suggests the need for varied punctures to allow the medication to reach the lesion in all its extension and depth [13]. Kato et al [14] showed that the concentration of 5% Ethamolin® performed better than 1.25% and 2.5% for sclerotherapy of oral vascular lesions measuring up to 20mm.…”

Remoção De Hemangioma Labial Através Da Técnica De Esclerotorapia Medicamentosa

“…É importante ressaltar que por mais que o HEM trate-se de uma lesão benigna, em alguns casos, pode ocasionar a compressão das estruturas adjacentes, ulceras e infecções secundárias. Cabendo ao profissional a atenção necessária para o diagnóstico e o tratamento (KATO et al, 2020).…”

“…Apesar da literatura apontar para possíveis efeitos adversos, como: necrose, dor e ulceração, no uso do oleato de monoetanolamina 5% sem diluição, nenhuma dessas condições foram observadas neste caso relatado. Esta terapêutica apesar de ir de encontro à diversos estudos, apresenta suporte científico na pesquisa mais recente de Kato et al (2020), estes autores utilizam o Ethamolin com e sem diluição em 30 pacientes e demonstraram que o uso desta substância sem diluição apresenta melhores resultados e efeitos adversos similares aos que são apresentados no uso deste composto diluído na aplicação intralesional em hemangiomas menores que 20mm.…”

“…Kato et al (2020) demonstram que quando o ethamolin não é diluído, o volume da dose é menor, assim como as aplicações. Contudo, há de se considerar também o nível da dose máxima para o procedimento seguro.…”